Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

In Part 1 (currently ongoing), between February 6, 2024, and December 27, 2024, 322 adults were screened, of whom 75 (aged 59-89 years) met NIA-AA and IPA criteria. Of these, 23 met clinical criteria for ADP but were not positive for APS or APS2, despite meeting historical biomarker requirements. We will present detailed biomarker results on the population, including apolipoprotein E (apoE) proteotype, Aβ42/40 ratio, and p-tau217 ratio. Clinical presentation and related information will be detailed as well. Biomarkers, rather than syndromic presentation, are recommended as a mechanism by which to define AD biologically. Since biomarker data from patients presenting with clinical symptoms consistent with Alzheimer's disease dementia and psychosis are sparse, we present biomarker data in a rigorously phenotyped population. These results can also inform the design and execution of clinical trials in ADP in the future.

What this study adds

Evidence grade: Low

This is a trial of 322 participants. This ongoing study presents plasma biomarker data in people with Alzheimer's disease psychosis, and notes that 23 participants met clinical criteria for the condition but were not positive on amyloid tests. The results are intended to inform future clinical trial design, not to treat or prevent the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Dirks, B., Friend, S., Howell, B., Murphy, C. M., Zhang, P. M., Feng, X., et al. (2025). Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_106556

Vancouver

Dirks B, Friend S, Howell B, Murphy CM, Zhang PM, Feng X, et al. Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_106556. PMID: 41451623.

BibTeX

@article{dirks2025-41451623,
  author  = {Dirks, Bryan and Friend, Samantha and Howell, Becky and Murphy, Christine M and Zhang, Peter M and Feng, Xiaoshu and Pathak, Sanjeev S},
  title   = {{Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70859_106556},
  pmid    = {41451623},
  url     = {https://doi.org/10.1002/alz70859_106556}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This ongoing study presents plasma biomarker data in people with Alzheimer's disease psychosis, and notes that 23 participants met clinical criteria for the condition but were not positive on amyloid tests. The results are intended to inform future clinical trial design, not to treat or prevent the disease.

Study details

How this study scored 33/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 0 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 33 of 100.33 of 100 points earned67 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 322 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 0 / 4 Last-listed author Sanjeev S Pathak: h-index 3 (OpenAlex, whole career)
Institution's track record 0 / 3 Acadia Pharmaceuticals (United States): institution h-index 94 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41451623)
Free to read 2 / 2 Free to read
Total 33 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →